Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q3 2022 · 10-Q
Revenue$156.40M$156.40M−6.5% vs Q3 2021 Net Income-$35.10M-$35.10MN/M vs Q3 2021 EPS Diluted-$0.43-$0.43N/M vs Q3 2021 Operating Income-$45,000,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,500,000N/M Margins · derivedOperating margin-28.8%+19.0 pt vs Q3 2021
Net margin-22.4%−37.1 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 2, 2022 · 33 d after period end